STANFORD UNIVERSITY

Brendan, a Ph.D. in organic synthesis from Stanford, has worked in pharmaceuticals, biotech, and co-founded 1200 Pharma. He remains an investor, focusing on biotech stocks. Analyst's disclosure: beneficial long position in SMMT shares. Investment involves risk; this is not investment advice.

Newer anti-seizure meds, like lamotrigine and levetiracetam, pose no risk to fetal neurodevelopment, according to a study tracking 387 children up to age 6. No differences in language scores were found between children exposed to these drugs in utero and those who were not.

Brendan, a Ph.D. in organic synthesis from Stanford, worked at Merck and biotech start-ups before co-founding 1200 Pharma. He remains an investor in biotech stocks and holds positions in BGNE and ABBV. This article is his own opinion and not investment advice.

The 'Nuclear Imaging Equipment Pipeline Report, 2024 Update' provides comprehensive details on pipeline products, clinical trials, and key companies involved in nuclear imaging equipment development, aiding strategic R&D, market entry, and mergers and acquisitions.

Organs age differently; heart may age faster than brain. 'Aging clocks' measure biological age via protein markers. Premature aging increases risks like heart failure and Alzheimer's. Understanding organ-specific aging could lead to personalized treatments and lifestyle changes to manage aging.

Stanford Medicine researchers used a CRISPR-based gene-screening method to identify a gene linked to doxorubicin-induced heart damage, and found a potential drug to protect heart cells.

FDA approves acoramidis (Attruby), a drug developed at Stanford Medicine for ATTR-CM, offering improved survival rates and quality of life. The drug, originally AG10, was developed through the SPARK program and clinical trials showed better efficacy than existing treatments.

Brendan, a Ph.D. in organic synthesis from Stanford, worked at Merck and biotech start-ups before co-founding 1200 Pharma. He remains an investor, focusing on biotech stocks. Currently long AMGN stock and considering adding to the position, with a smaller long position in LLY. Investment involves risk; this discussion is a framework for understanding price movement, not investment advice.

Children of mothers who took newer antiseizure medications during pregnancy showed no worse neurodevelopmental outcomes at age 6, according to a long-term NIH-funded study published in JAMA Neurology. The study found no differences in language scores between children exposed to the medications and those who were not, with most mothers taking lamotrigine, levetiracetam, or a combination. High doses of folate during pregnancy were associated with better cognitive and behavioral outcomes.

SEL-212, a monthly two-component infusion therapy, improved patient-reported outcomes (PROs) in refractory gout patients after 3 doses, with further improvement after 6 doses, as shown in Phase 3 trials presented at ACR Convergence 2024.